Zegerid Santarus, Inc. - Treatment for Heartburn/GERD, Erosive Esophagitis, Duodenal Ulcers
Zegerid is approved for short-term treatment (4-8 wks) of active duodenal ulcer; treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD); short-term treatment (4-8 wks) of erosive esophagitis which has been diagnosed by endoscopy; and maintenance of healing of erosive esophagitis.Posted: June 2004
Related articles
- Santarus Announces FDA Action Date of February 27, 2006 for Zegerid Capsules NDA - February 24, 2006
- Santarus Announces FDA Acceptance of New Drug Application For Zegerid Chewable Tablets - July 26, 2005
- Santarus Announces FDA Acceptance of New Drug Application For Zegerid Capsules; FDA Action Expected in Early 2006 on NDA for First Immediate-Release Proton Pump Inhibitor in Capsule Formulation - June 28, 2005
- Santarus Submits New Drug Application for Zegerid Chewable Tablets - May 27, 2005
- Santarus Submits New Drug Application for Zegerid Capsules; NDA for First Immediate-Release PPI Capsule Submitted Ahead of Previously Announced Third Quarter Target - April 28, 2005
- FDA Accepts for Filing Santarus' New Drug Application for Rapinex Powder for Oral Suspension 40mg - April 29, 2004
Zegerid (omeprazole and sodium bicarbonate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
